{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:57:41Z","timestamp":1788587861983,"version":"build-2803163510"},"reference-count":41,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa\/foscarbidopa (LDp\/CDp), delivered as a continuous 24\u2010h\/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp\/CDp has been widely utilized since becoming commercially available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To provide practical guidance for clinicians on the real\u2010world use of LDp\/CDp, including information on patient selection, treatment initiation, dose adjustments, and long\u2010term management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review included investigator experience from studies of LDp\/CDp and insights from clinicians with real\u2010world experience with LDp\/CDp, addressing many critical questions that clinicians may have when initiating and managing patients on therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Continuous 24\u2010h infusion enables consistent, individualized symptom control, with improvements in motor fluctuations and quality of life. LDp\/CDp therapy can be initiated, adjusted, and maintained in outpatient settings without hospitalization. While infusion site events are common, they are typically mild to moderate and manageable. Early detection and intervention are important for managing infusion site events. Systemic adverse events associated with dopaminergic therapies (eg, psychosis, hallucinations, nightmares), may require infusion rate adjustment, particularly at night. Setting clear expectations is key to successful therapy adoption and maintenance. It is essential to educate patients, care partners, and clinical teams.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LDp\/CDp is a new treatment option for advanced PD (aPD). Treatment success depends on education, selecting appropriate patients, setting patient expectations, implementing individualized dosing strategies, and managing adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.70489","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:00:17Z","timestamp":1768557617000},"page":"1601-1611","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Considerations for Initiation and Maintenance of Foslevodopa\/Foscarbidopa for Advanced Parkinson's Disease"],"prefix":"10.1002","volume":"13","author":[{"given":"K. Ray","family":"Chaudhuri","sequence":"first","affiliation":[{"name":"PDNMG, King's College Hospital London  Dubai United Arab Emirates"},{"name":"PDNMG, King's College Hospital  London UK"},{"name":"Dementech Clinical Neuroscience Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-8262","authenticated-orcid":false,"given":"Bruno","family":"Bergmans","sequence":"additional","affiliation":[{"name":"Department of Neurology, AZ St\u2010Jan Brugge  Bruges Belgium"},{"name":"Department of Neurology Ghent University Hospital  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Freire\u2010Alvarez","sequence":"additional","affiliation":[{"name":"Department of Neurology Movement Disorders Unit, Hospital General Universitario of Elche  Elche Spain"},{"name":"Department of Neurology IMED Elche Hospital  Elche Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Hopes","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery University Hospital of Nancy  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew S.","family":"Kern","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Kirsner","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Hospital  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-2002","authenticated-orcid":false,"given":"Giulia","family":"Lazzeri","sequence":"additional","affiliation":[{"name":"The Parkinson Institute, ASST Gaetano Pini\u2010CTO  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mendes\u2010Bastos","sequence":"additional","affiliation":[{"name":"Dermatology Center, Hospital CUF Descobertas  Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Neurology Juntendo University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Clinical Sciences Lund University  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Poplawska\u2010Domaszewicz","sequence":"additional","affiliation":[{"name":"PDNMG, King's College Hospital London  Dubai United Arab Emirates"},{"name":"PDNMG, King's College Hospital  London UK"},{"name":"Department of Neurology Poznan University of Medical Sciences  Poznan Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[{"name":"Parkinson's and Movement Disorder Division, Parkinson Foundation Center of Excellence University of Kansas Medical Center  Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8606-8385","authenticated-orcid":false,"given":"Yuval","family":"Ramot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hadassah Medical Center  Jerusalem Israel"},{"name":"Faculty of Medicine The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Seppi","sequence":"additional","affiliation":[{"name":"Department of Neurology, District Hospital Kufstein Innsbruck Medical University  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Warnecke","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurorehabilitation, Klinikum Osnabr\u00fcck Academic Teaching Hospital of the University of M\u00fcnster  Osnabr\u00fcck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wiggins","sequence":"additional","affiliation":[{"name":"Department of Neurology, Novant Health Presbyterian Medical Center  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha B.","family":"Shah","sequence":"additional","affiliation":[{"name":"AbbVie Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[{"name":"AbbVie Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Fritz","sequence":"additional","affiliation":[{"name":"AbbVie Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Onuk","sequence":"additional","affiliation":[{"name":"AbbVie Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Department of Neurology Florida International University  Miami Florida USA"},{"name":"Parkinson's Disease and Movement Disorders Center of Boca Raton  Boca Raton Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100239"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00799"},{"key":"e_1_2_8_4_1","unstructured":"AbbVie.VYALEV (foscarbidopa and foslevodopa) prescribing information;2024. Accessed March 21 2025.www.rxabbvie.com\/pdf\/vyalev_pi.pdf."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00635-4"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-212813"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00533-1"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00400-8"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14018"},{"key":"e_1_2_8_10_1","first-page":"322","article-title":"Long\u2010term safety and efficacy for motor fluctuations and quality of life with foslevodopa\/foscarbidopa in patients with advanced Parkinson's disease (PD): interim results from an ongoing open label extension","volume":"39","author":"Bergquist F","year":"2024","journal-title":"Mov Disord"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208722"},{"key":"e_1_2_8_12_1","first-page":"322","article-title":"Long\u2010term safety and efficacy of foscarbidopa\/foslevodopa in patients with advanced Parkinson's disease (PD): results from an ongoing phase 3 open\u2010label extension with up to 1 year follow\u2010up","volume":"39","author":"Hauser R","year":"2024","journal-title":"Mov Disord"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100292"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30121"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30069"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1799-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1502165"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4047392"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7537924"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.07.020"},{"key":"e_1_2_8_21_1","unstructured":"AntoniniA BergmansB KernD et al.Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson's disease treated with foslevodopa\/foscarbidopa subcutaneous 24 hour infusion Mov Disord.2023;38(suppl 1).https:\/\/www.mdsabstracts.org\/abstract\/improvement\u2010in\u2010motor\u2010symptoms\u2010and\u2010quality\u2010of\u2010life\u2010in\u2010patients\u2010with\u2010an\u2010earlier\u2010stage\u2010of\u2010advanced\u2010parkinsons\u2010disease\u2010treated\u2010with\u2010foslevodopa\u2010foscarbidopa\u2010subcutaneous\u201024\u2010hour\u2010infusion\/."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70193"},{"issue":"1","key":"e_1_2_8_23_1","first-page":"244","article-title":"Cluster analysis of patient characteristics associated with up to 100% \u201coff\u201d time improvement from two phase 3 trials","volume":"32","author":"Dashtipour K","year":"2025","journal-title":"Eur J Neurol"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","unstructured":"JostWH BergquistF EvansA et al.Real\u2010world safety and effectiveness of foslevodopa\/foscarbidopa in Parkinson's disease: ROSSINI study 6\u2010month interim results (OPP12). Paper presented at the Movement Disorder Society 2025 Annual Meeting October 8 2025.","DOI":"10.1007\/s40120-026-00948-6"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000204663"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40734-016-0036-9"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70060"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70324"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00421-9"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00317-x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12141"},{"key":"e_1_2_8_32_1","unstructured":"AbbVie.Getting familiar with your delivery system;2025. Accessed September 25 2025.https:\/\/www.vyalev.com\/delivery-system."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29410"},{"key":"e_1_2_8_34_1","unstructured":"EMC.Produodopa 240 mg\/ml + 12 mg\/ml solution for infusion;2024. Accessed July 31 2025.https:\/\/www.medicines.org.uk\/emc\/product\/15213\/smpc\/print"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70245"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1017\/9781009222648"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30239-4"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2025.100359"},{"key":"e_1_2_8_39_1","volume-title":"Clinical Practice Guideline for the Management of Patients with Parkinson's Disease. Ministry of Health, Social Services, and Equality. Institute of Health Sciences of Aragon","year":"2014"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.11.262"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2021.1851198"},{"issue":"10","key":"e_1_2_8_42_1","first-page":"2317","article-title":"Treatment of Parkinson's disease psychosis\u2010a systematic review and multi\u2010methods approach","volume":"12","author":"Rose O","year":"2024","journal-title":"Biomedicine"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70489","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:12:43Z","timestamp":1784293963000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/mdc3.70489"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70489","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"2025-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}